News | September 07, 2023
Biocon Biologics completes integration of Viatris Biosimilars’ business in North America
Biocon Biologics recently acquired the global biosimilars business of its long-term partner Viatris
Biocon Biologics recently acquired the global biosimilars business of its long-term partner Viatris
Adding 20,000 liters of installed biologics drug substance manufacturing capacity
Rapid card test kits for iScreen malaria card antigen (Pf/Pv) & iScreen dengue NS1
The booster vaccine can be administered safely to individuals who have received two doses of either Covaxin or Covishield
Columvi is part of Roche's industry-leading portfolio of T-cell engaging bispecific antibodies in non-Hodgkin lymphoma, which also includes the recently approved Lunsumio to treat follicular lymphoma
One thousand times more soluble than L-cystine at neutral pH
Acquisition enhances Freenome's product portfolio, including autoantibody platform with additional biomarkers important in cancer detection
This approval reflects Biocon Biologics' compliance with the highest international regulatory standards
New high-tech facility in Biberach offers attractive workplaces for more than 500 scientists
The milestone of operating continuously a very complex system for over two years has demonstrated the effectiveness of integrated laboratory automation solutions
Subscribe To Our Newsletter & Stay Updated
